After a traumatic event, injured workers may want to avoid the scene of the accident. But returning to work could help them heal.
The U.S. Food and Drug Administration (FDA) recently approved Journavx (suzetrigine), a novel non-opioid medication developed by Vertex Pharmaceuticals for the treatment of moderate to severe acute pain in adults. This approval, announced on January 30, 2025, marks a significant milestone in pain management, introducing the first new class of oral medication for acute pain in over two decades.
Industry expert Michael Cwynar of Enlyte discusses how to strike the right balance between AI innovation and professional expertise in today’s rapidly evolving tech landscape.
Enlyte's field case management provides empathetic, innovative support for injured employees, guiding recovery with tailored solutions. Discover how our comprehensive approach can enhance your workers' compensation outcomes.
As reported by the Bureau of Labor and Statistics (BLS) in January 2025 for December 2024, the United States consumer price index increased to 2.9% over the preceding 12 months which is 0.5% higher than reported in October 2024.
Explore vocational case management's role in workers' compensation. Learn about services, qualifications, benefits, and when to refer for vocational rehabilitation to improve return-to-work outcomes and reduce claim costs.
Download the Comprehensive Guide to Outcomes-Based Networks and discover how strategic channeling, advanced analytics, and evidence-based care are reshaping the future of workers’ compensation.